Atticus Wealth Management’s DexCom DXCM Stock Holding History

Atticus Wealth Management’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-43	Closed	-$3.75K	–	315
2025 Q2	$3.75K	Buy	+43	New	+$3.37K	﹤0.01%	537

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Atticus Wealth Management's DXCM Position: Q3 2025 in Review

Atticus Wealth Management sold out of DexCom (DXCM) in Q3 2025, closing a stake of 43 shares — an estimated $3.75K sold.

Atticus Wealth Management first reported a position in DXCM in Q2 2025 and held it in 1 quarter. The position peaked at $3.75K in Q2 2025. 911 funds tracked by Wall St. Rank hold DXCM as of Q3 2025.

Atticus Wealth Management reported no remaining DexCom position as of Q3 2025 after selling out during the quarter.
Atticus Wealth Management sold 43 DexCom shares in Q3 2025, an estimated $3.75K.
Atticus Wealth Management first reported a position in DexCom in Q2 2025 and held it in 1 quarter.
Atticus Wealth Management's DexCom position peaked at $3.75K in Q2 2025.
911 funds tracked by Wall St. Rank held DexCom as of Q3 2025.

Based on Atticus Wealth Management's 13F filing for Q3 2025, filed 7 Nov 2025.